AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing
When AstraZeneca wagered $200 million in cash upfront to bring in Ionis’ antisense candidate for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), it was not shy about introducing a potentially best-in-class drug in a space that, despite treatments from Alnylam, Pfizer and Ionis itself, still offers limited options.
It now has the late-stage data to back up that claim — although it’s holding the numbers back.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.